KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Non-Current Deffered Revenue (2022 - 2024)

Opko Health's Non-Current Deffered Revenue history spans 3 years, with the latest figure at $7000.0 for Q3 2024.

  • For Q3 2024, Non-Current Deffered Revenue fell 94.85% year-over-year to $7000.0; the TTM value through Sep 2024 reached $7000.0, down 94.85%, while the annual FY2024 figure was $7000.0, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $7000.0 in Q3 2024 per OPK's latest filing, roughly flat from $7000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $140000.0 in Q2 2023 to a low of $7000.0 in Q4 2023.
  • Average Non-Current Deffered Revenue over 3 years is $63142.9, with a median of $7000.0 recorded in 2023.
  • The largest YoY upside for Non-Current Deffered Revenue was 94.85% in 2024 against a maximum downside of 95.0% in 2024.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $138000.0 in 2022, then tumbled by 94.93% to $7000.0 in 2023, then changed by 0.0% to $7000.0 in 2024.
  • Per Business Quant, the three most recent readings for OPK's Non-Current Deffered Revenue are $7000.0 (Q3 2024), $7000.0 (Q2 2024), and $7000.0 (Q1 2024).